Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR1019B
- Development stage
- Phase 3
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BR1019B is an investigational drug developed by Boryung Pharmaceutical as part of a combination therapy for the treatment of essential hypertension and type 2 diabetes mellitus. It is being evaluated in phase 3 clinical trials, typically in combination with other agents such as BR1019A and related compounds. The precise mechanism of action for BR1019B has not been defined or disclosed publicly. The drug is classified under antihyperglycaemics and antihypertensives, indicating its intended dual role in lowering blood glucose levels and reducing blood pressure. Clinical development is ongoing, primarily in South Korea[1][2][7].
Beyond the preview
Go deeper on BR1019B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR1019B.